Zobrazeno 1 - 10
of 178
pro vyhledávání: '"Pasquale Narciso"'
Autor:
Chiara Tommasi, Mauro Zaccarelli, Claudio Angeletti, Adriana Ammassari, Anna Loredana Gallo, Massimo Tempestilli, Maria Letizia Giancola, Emanuele Nicastri, Pierluca Piselli, Carmela Pinnetti, Rita Bellagamba, Andrea Antinori, Pasquale Narciso
Publikováno v:
AIDS (London, England). 33(3)
OBJECTIVE Antiretrovirals with long half-lives, such as tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) and efavirenz (EFV), are suitable for reduced frequency dosing, with potential for improved adherence and reduced toxicity and costs. The ob
Autor:
Piero Ghirga, P. De Nardo, T. Ascoli Bartoli, Paola Mencarini, Andrea Baiocchini, Maria Letizia Giancola, Rita Bellagamba, Emanuele Nicastri, Alessandra Oliva, Pasquale Narciso, F. Del Nonno, Angela Corpolongo
Publikováno v:
Respiratory Medicine Case Reports
The diagnosis of sarcoidosis in a patient living with HIV infection is an uncommon event and a challenge for clinicians. Clinical manifestations are variable and fluctuating depending to adherence to ARV therapy and to the level of CD4 count. We anal
Autor:
Rita Bellagamba, Andrea Antinori, Pasquale Narciso, Martina Ricottini, Mauro Zaccarelli, Maria Letizia Giancola, Pietro Balestra, Chiara Tommasi, Patrizia Lorenzini, Massimo Tempestilli, Carmela Pinnetti, Anna Loredana Gallo, Emanuele Nicastri, Claudio Angeletti, Adriana Ammassari
Publikováno v:
AIDS research and human retroviruses. 34(11)
Autor:
Eleonora Cimini, Antonio D'Avolio, Massimo Tempestilli, Federica Elisei, Federico Martini, Leopoldo Paolo Pucillo, Tonino Alonzi, Pasquale Narciso, Emanuele Nicastri, Germana Grassi
Publikováno v:
Journal of Antimicrobial Chemotherapy. 69:1760-1766
Received 30 October 2013; returned 17 December 2013; revised 11 February 2014; accepted 17 February 2014Background: Antiretroviral therapy has considerably reduced HIVdisease progression, but complete eradicationofHIVcannotactuallybeachieved.Moreover
Autor:
Pasquale Narciso, Tecla Gasperi, Marzia Montalbano, Gianpiero D'Offizi, Paolo Ascenzi, Leopoldo Paolo Pucillo, Massimo Tempestilli, Antonio D'Avolio, Elisa Milano
Publikováno v:
IUBMB Life. 65:800-805
Telaprevir is a direct acting antiviral agent, used with pegylated interferon and ribavirin for the management of chronic hepatitis C virus (HCV) genotype 1 infection, in patients not responding to therapy with pegylated interferon and ribavirin only
Autor:
Guido Palamara, Alessandra Latini, Evangelo Boumis, Carlo Federico Perno, Chiara Tommasi, Federica Forbici, Claudia Alteri, Francesca Ceccherini-Silberstein, Rita Bellagamba, Caterina Gori, Maria Mercedes Santoro, Andrea Antinori, Pasquale Narciso, Daniele Armenia, Raffaella Libertone, Carmela Pinnetti, Vanni Borghi, Mario Santoro, Emanuele Nicastri, Cristina Mussini, Lavinia Fabeni, Adriana Ammassari, Valerio Tozzi, Andrea Calcagno, Valentina Svicher, Massimo Andreoni, Giovanni Di Perri, Philippe Flandre, A. R. Buonomini
Publikováno v:
Antiviral Therapy; Vol 18
Background We tested whether pre-HAART viraemia affects the achievement and maintenance of virological success in HIV-1-infected patients starting modern first-line therapies. Methods A total of 1,430 patients starting their first HAART (genotype-tai
Autor:
Vincenzo Fragola, Rita Bellagamba, M Massella, R De Vita, Pasquale Narciso, M Rizzica, Luca Fracasso, Valerio Tozzi, Jelena Ivanovic
Publikováno v:
Patient Preference and Adherence, Vol 2011, Iss default, Pp 223-228 (2011)
Patient preference and adherence
Patient preference and adherence
M Massella¹, J Ivanovic², R Bellagamba², R De Vita³, L Fracasso³, V Tozzi², V Fragola¹, M Rizzica², P Narciso²¹Istituto Superiore Sanità, Rome, Italy; ²National Institute for Infectious Disease – Lazzaro Spallanzani, Rome, Italy; ³Regi
Autor:
Guido Palamara, Alessandra Latini, Giuseppe Tambussi, Paolo Monini, Adriano Lazzarin, Barbara Ensoli, Gianpiero D'Offizi, Maria Josè Ruiz Alvarez, Enrico Garaci, Barbara Collacchi, Massimo Giuliani, Arianna Scoglio, Aldo Di Carlo, Chiara Tassan Din, Marina Giulianelli, Maria Carta, Andrea Antinori, Pasquale Narciso, Stefania Bellino, Antonella Tripiciano, Olimpia Longo, Mauro Magnani, Fabrizio Ensoli, Valeria Fiorelli, Vittorio Francavilla, Angela Arancio, Giovanni Paniccia, Raffaele Visintini
Publikováno v:
Vaccine. 28:371-378
The native HIV-1 Tat protein was chosen as vaccine candidate for phase I clinical trials based on its role in the natural infection and AIDS pathogenesis, on the association of Tat-specific immune response with the asymptomatic stage as well as on it
Autor:
Jelena, Ivanovic, Emanuele, Nicastri, Anceschi, Maurizio Marco, Paolo, Ascenzi, Fabrizio, Signore, Giuseppe, Pisani, Cristina, Vallone, Elisabetta, Mattia, Stefania, Notari, Massimo, Tempestilli, Leopoldo, Pucillo, Pasquale, Narciso, Pregnancy, Hiv Infection Pancoh Newborn Clinical Outcome Group, I. N.
Publikováno v:
Current HIV Research. 7:620-625
Although it is well known that antiretroviral drugs (ARVs) across the placenta in different extents, few data are available concerning the impact of the transplacental passage of ARVs on newborn outcome. The aim of this study is to evaluate the trans
Autor:
Vittorio Francavilla, Olimpia Longo, Adriano Lazzarin, A. Di Carlo, Mauro Magnani, Antonella Tripiciano, Guido Palamara, Fabrizio Ensoli, Angela Arancio, Giuseppe Tambussi, Marinella Giulianelli, Gianpiero D’Offizi, Paolo Monini, C. Tassan Din, Arianna Scoglio, Maria Carta, Giovanni Paniccia, Raffaele Visintini, Pasquale Narciso, Maria Elena Laguardia, Massimo Giuliani, Stefania Bellino, Andrea Antinori, Massimo Campagna, Barbara Ensoli, Valeria Fiorelli, Barbara Collacchi
Publikováno v:
ResearcherID
The native HIV-1 Tat protein was chosen as vaccine candidate for phase I clinical trials in both uninfected (ClinicalTrials.gov identifier: NCT00529698) and infected volunteers (ClinicalTrials.gov identifier: NCT00505401). The rationale was based on